Protein kinase CK2 inhibitors: A patent review

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 9, 2012, Pages 1081-1097

  Cozza, Giorgio ^a   Pinna, Lorenzo A ^a   Moro, Stefano ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Casein kinase 2; CK2 inhibitors; Protein kinase CK2

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CASEIN KINASE II; CASEIN KINASE II INHIBITOR; CX 4945; HOLOENZYME; IMIDAZOLE DERIVATIVE; PHOSPHOTRANSFERASE INHIBITOR; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRAZOLOTRIAZINE; PYRIMIDONE; TETRABROMOBENZIMIDAZOLE; UNCLASSIFIED DRUG;

BINDING SITE; CATALYSIS; CHEMICAL STRUCTURE; DRUG DEVELOPMENT; DRUG RESEARCH; DRUG STRUCTURE; HUMAN; NONHUMAN; PATENT; PROTEIN FUNCTION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CASEIN KINASE II; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG DESIGN; HUMANS; NEOPLASMS; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS;

EID: 84865519039     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.717615     Document Type: Review

References (81)

1. Burnett G, Kennedy EP. The enzymatic phosphorylation of proteins. J Biol Chem 1954;211(2):969-80. The first paper reporting the identification of protein kinase CK2.
2. Meggio F, Pinna LA. One-thousand-andone substrates of protein kinase CK2? FASEB J 2003;17(3):349-68 (Pubitemid 36292951)
3. Salvi M, Sarno S, Cesaro L, et al. Extraordinary pleiotropy of protein kinase CK2 revealed by weblogo phosphoproteome analysis. Biochim Biophys Acta 2009;1793(5):847-59
4. Cozza G, Bortolato A, Moro S. How druggable is protein kinase CK2? Med Res Rev 2010;30(3):419-62
5. Cozza G, Meggio F, Moro S. The dark side of protein kinase CK2 inhibition. Curr Med Chem 2011;18(19):2867-84
6. Ruzzene M, Di Maira G, Tosoni K, Pinna LA. Assessment of CK2 constitutive activity in cancer cells. Methods Enzymol 2010;484:495-514
7. Guerra B, Issinger OG. Protein kinase CK2 in human diseases. Curr Med Chem 2008;15(19):1870-86. A nice overview of the role of protein kinase CK2 in human diseases.
8. Pinna LA. The raison d'etre of constitutively active protein kinases: The lesson of CK2. Acc Chem Res 2003;36(6):378-84
9. Marin O, Sarno S, Boschetti M, et al. Unique features of HIV-1 rev protein phosphorylation by protein kinase CK2 ('casein kinase-2'). FEBS Lett 2000;481(1):63-7 (Pubitemid 30662378)
10. Poletto G, Vilardell J, Marin O, et al. The regulatory beta subunit of protein kinase CK2 contributes to the recognition of the substrate consensus sequence. A study with an eIF2 beta-derived peptide. Biochemistry 2008;47(32):8317-25
11. Meggio F, Boldyreff B, Marin O, et al. The effect of polylysine on casein-kinase-2 activity is influenced by both the structure of the protein/peptide substrates and the subunit composition of the enzyme. Eur J Biochem 1992;205(3):939-45
12. Sarno S, Ghisellini P, Pinna LA. Unique activation mechanism of protein kinase CK2. The N-terminal segment is essential for constitutive activity of the catalytic subunit but not of the holoenzyme. J Biol Chem 2002;277(25):22509-14 (Pubitemid 34967224)
13. Cristiani A, Costa G, Cozza G, et al. The role of the N-terminal domain in the regulation of the "Constitutively Active" conformation of protein kinase CK2alpha: Insight from a molecular dynamics investigation. ChemMedChem 2011;6(7):1207-16
14. Lolli G, Pinna LA, Battistutta R. Structural determinants of protein kinase CK2 regulation by autoinhibitory polymerization. ACS Chem Biol 2012;7(7):1158-63
15. Battistutta R. Protein kinase CK2 in health and disease: Structural bases of protein kinase CK2 inhibition. Cell Mol Life Sci 2009;66(11-12):1868-89
16. Sarno S, Papinutto E, Franchin C, et al. ATP site-directed inhibitors of protein kinase CK2: An update. Curr Top Med Chem 2011;11(11):1340-51. An exhaustive overview of the protein kinase CK2 inhibitors.
17. Siddiqui-Jain A, Drygin D, Streiner N, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 2010;70(24):10288-98
18. Pierre F, Chua PC, O'Brien SE, et al. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Mol Cell Biochem 2011;356(1-2):37-43
19. Ferguson AD, Sheth PR, Basso AD, et al. Structural basis of CX-4945 binding to human protein kinase CK2. FEBS Lett 2011;585(1):104-10
20. Prudent R, Moucadel V, Nguyen CH, et al. Antitumor activity of pyridocarbazole and benzopyridoindole derivatives that inhibit protein kinase CK2. Cancer Res 2010;70(23):9865-74
21. Kinoshita T, Sekiguchi Y, Fukada H, et al. A detailed thermodynamic profile of cyclopentyl and isopropyl derivatives binding to CK2 kinase. Mol Cell Biochem 2011;356(1-2):97-105
22. Meggio F, Shugar D, Pinna LA. Ribofuranosyl-benzimidazole derivatives as inhibitors of casein kinase-2 and casein kinase-1. Eur J Biochem 1990;187(1):89-94. The first paper reporting the first protein kinase CK2 inhibitor. (Pubitemid 20040364)
23. Zandomeni R, Zandomeni MC, Shugar D, Weinmann R. Casein kinase type II is involved in the inhibition by 5,6-dichloro-1-beta-Dribofuranosylbenzimidazole of specific RNA polymerase II transcription. J Biol Chem 1986;261(7):3414-19 (Pubitemid 17204962)
24. Raaf J, Brunstein E, Issinger OG, Niefind K. The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules. Chem Biol 2008;15(2):111-17 (Pubitemid 351253616)
25. Gianoncelli A, Cozza G, Orzeszko A, et al. Tetraiodobenzimidazoles are potent inhibitors of protein kinase CK2. Bioorg Med Chem 2009;17(20):7281-9
26. Sarno S, Moro S, Meggio F, et al. Toward the rational design of protein kinase casein kinase-2 inhibitors. Pharmacol Ther 2002;93(2-3):159-68 (Pubitemid 34615557)
27. Cozza G, Mazzorana M, Papinutto E, et al. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. Biochem J 2009;421(3):387-95
28. Cozza G, Bonvini P, Zorzi E, et al. Identification of ellagic acid as potent inhibitor of protein kinase CK2: A successful example of a virtual screening application. J Med Chem 2006;49(8):2363-6
29. Cozza G, Gianoncelli A, Bonvini P, et al. Urolithin as a converging scaffold linking ellagic acid and coumarin analogues: Design of potent protein kinase CK2 inhibitors. ChemMedChem 2011;6(12):2273-86 A nice example of design of novel protein kinase CK2 inhibitors.
30. Nie Z, Perretta C, Erickson P, et al. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5] triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities. Bioorg Med Chem Lett 2008;18(2):619-23
31. Nie Z, Perretta C, Erickson P, et al. Structure-based design, synthesis, and study of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase CK2. Bioorg Med Chem Lett 2007;17(15):4191-5 (Pubitemid 47021399)
32. Battistutta R, Cozza G, Pierre F, et al. Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer. Biochemistry 2011;50(39):8478-88
33. Niefind K, Guerra B, Ermakowa I, Issinger OG. Crystal structure of human protein kinase CK2: Insights into basic properties of the CK2 holoenzyme. EMBO J 2001;20(19):5320-31 (Pubitemid 32959451)
34. Laudet B, Moucadel V, Prudent R, et al. Identification of chemical inhibitors of protein-kinase CK2 subunit interaction. Mol Cell Biochem 2008;316(1-2):63-9
35. Pagano MA, Marin O, Cozza G, et al. Cystic fibrosis transmembrane regulator fragments with the Phe508 deletion exert a dual allosteric control over the master kinase CK2. Biochem J 2010;426(1):19-29
36. Hung MS, Xu Z, Lin YC, et al. Identification of hematein as a novel inhibitor of protein kinase CK2 from a natural product library. BMC Cancer 2009;9:135
37. Prudent R, Moucadel V, Lopez-Ramos M, et al. Expanding the chemical diversity of CK2 inhibitors. Mol Cell Biochem 2008;316(1-2):71-85
38. Prudent R, Moucadel V, Laudet B, et al. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2. Chem Biol 2008;15(7):683-92 (Pubitemid 351957909)
39. Moucadel V, Prudent R, Sautel CF, et al. Antitumoral activity of allosteric inhibitors of protein kinase CK2. Oncotarget 2011;2(12):997-1010
40. Mukolaiovych YS. The use of 4-substituted 3-carboxyquinolines as protein kinase CK2 inhibitors. UA68984; 2004. A first patent referring to a protein kinase CK2 inhibitor.
41. Mukolaiovych YS. The use of 4,5,6,7- tetrahalogeno-1,3-isoindolyndions as protein kinase CK2 inhibitors. UA69165; 2004
42. Golub AG, Yakovenko OY, Bdzhola VG, et al. Evaluation of 3-carboxy-4(1H)- quinolones as inhibitors of human protein kinase CK2. J Med Chem 2006;49(22):6443-50 (Pubitemid 44657440)
43. Golub AG, Yakovenko OY, Prykhod'ko AO, et al. Evaluation of 4,5,6,7-tetrahalogeno-1H-isoindole-1,3 )-diones as inhibitors of human protein kinase CK2. Biochim Biophys Acta 2008;1784(1):143-9
44. Fundacja Rozwoju Diagnostyki i Teratii. New derivatives of 4, 5, 6, 7-Tetrabromobenzimidazole and method of their preparation. WO2005092866; 2005
45. Pagano MA, Meggio F, Ruzzene M, et al. 2-dimethylamino-4,5,6,7- tetrabromo-1H-benzimidazole: A novel powerful and selective inhibitor of protein kinase CK2. Biochem Biophys Res Commun 2004;321(4):1040-4 (Pubitemid 39044414)
46. Exelixis, Inc. Pyrazolo-Pyrimidines as Casein Kinase II (CK2) modulators. WO2007048066; 2007
47. Exelixis, Inc. Pyrimidinones as Casein Kinase II (CK2) modulators. WO2008143759; 2008
48. INSERM. Protein-kinase CK2 inhibitors and their therapeutic applications. EP1911451; 2008
49. Cylene Pharmaceuticals. Serine-threonine protein kinase and PARP modulators. WO2008028168; 2008. This is the patent referring to the clinical trial candidate CX-4945.
50. Cylene Pharmaceuticals. Therapeutic kinase modulators. WO200997014; 2009
51. Cylene Pharmaceuticals. Novel protein kinase modulators. WO2010135571; 2010
52. Cylene Pharmaceuticals. Novel tricyclic protein kinase modulators. WO201135019; 2011
53. Cylene Pharmaceuticals. Polymorphs and salts of a kinase inhibitor. WO2011063398; 2011
54. Cylene Pharmaceuticals. Deuterated Serine-Threonine protein kinase modulators. WO2012054493; 2012
55. Cylene Pharmaceuticals. Novel protein kinase modulators. WO2010135571; 2010
56. Bachmann M, Moroy T. The serine/ threonine kinase Pim-1. Int J Biochem Cell Biol 2005;37(4):726-30
57. Small D, Levenstein M, Kim E, et al. STK-1, the human homolog of Flk-2/ Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA 1994;91(2):459-63 (Pubitemid 24041421)
58. Lyman SD. Biology of flt3 ligand and receptor. Int J Hematol 1995;62(2):63-73
59. Cylene Pharmaceuticals. Tricyclic compounds and pharmaceutical uses thereof. WO201135022; 2011
60. Cylene Pharmaceuticals. Rhodanines and related heterocycles as kinase inhibitors. WO2010148351; 2010
61. Toray Industries. Indoloquinoxaline carboxylic acid derivative or pharmacologically allowable salt thereof, and casein kinase 2 inhibitor containing the same active component. JP2010173971; 2010
62. Cylene Pharmaceuticals. Pyrazolopyrimidines and related heterocycles as CK2 inhibitors. WO2011068667; 2011
63. Cylene Pharmaceuticals. Pharmaceutically useful heterocycle-substituited lactams. WO201131979; 2011
64. Centre National de la Recherche Scientifique. Condensed pyridine derivatives useful as potent inhibitors of the protein kinase CK2. WO2011013002; 2011
65. Jose Joachim. Use of dibenzofuranone derivatives to inhibit kinases. WO2011161151; 2011
66. Bristol-Myers Squibb Co. Substituted Pyrrolotriazines as protein kinase inhibitors. WO2011123493; 2011
67. Cedars-Sinai Medical Center. Antiangiogenesis by inhibiting protein kinase CK2 activity. WO2004058185; 2004
68. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407(6801):249-57
69. Sato Y. Molecular mechanism of angiogenesis transcription factors and their therapeutic relevance. Pharmacol Ther 2000;87(1):51-60 (Pubitemid 30618987)
70. BIOREC. Use of CK2 inhibitor for the treatment and chemosensibilization of refractory tumors to anticancer drugs. WO2007098719; 2007
71. Perea SE, Reyes O, Puchades Y, et al. Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2). Cancer Res 2004;64(19):7127-9 (Pubitemid 39331026)
72. The Trustees of the University of Pennsylvania. Antiviral inhibition of Casein kinase II. WO2008060695; 2008
73. University of Rochester Medical Center. Targeting of Histone Deacetylase 2, Protein Kinase CK2, and Nuclear Factor NRF2 For Treatment of Inflammatory Diseases. US2012022129; 2010. An interesting application patent reporting the possible role of protein kinase CK2 on the HDAC2.
74. Barnes PJ. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161(2 Pt 1):342-4 (Pubitemid 30129436)
75. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005;352(19):1967-76 (Pubitemid 40638367)
76. Yang SR, Valvo S, Yao H, et al. IKK alpha causes chromatin modification on pro-inflammatory genes by cigarette smoke in mouse lung. Am J Respir Cell Mol Biol 2008;38(6):689-98 (Pubitemid 351841570)
77. Rajendrasozhan S, Yang SR, Edirisinghe I, et al. Deacetylases and NF-kappaB in redox regulation of cigarette smoke-induced lung inflammation: Epigenetics in pathogenesis of COPD. Antioxid Redox Signal 2008;10(4):799-811 (Pubitemid 351225898)
78. Ito K, Caramori G, Lim S, et al. Expression and activity of histone deacetylases in human asthmatic airways. Am J Respir Crit Care Med 2002;166(3):392-6 (Pubitemid 34864433)
79. Yang SR, Chida AS, Bauter MR, et al. Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages. Am J Physiol Lung Cell Mol Physiol 2006;291(1):L46-57
80. Tsai SC, Seto E. Regulation of histone deacetylase 2 by protein kinase CK2. J Biol Chem 2002;277(35):31826-33 (Pubitemid 34968989)
81. Cylene Pharmaceuticals. Combination therapies with CK2 modulators. WO2011011199; 2011